Aegirbio signs agreement with Salofa for the veterinary market and receives a first order worth approximately SEK 2 million.

Aegirbio has signed a non-exclusive agreement with the Finnish company Salofa Oy. The agreement is for veterinary applications and gives Salofa access to AegirBio's instruments and MagnetoImmunoAssay (MIA) for its own development of tests in veterinary medicine.

With this agreement, AegirBio will, via its subsidiary Magnasense Technologies OY, sell its existing MagniaReader to Salofa, which will bring it to market with proprietary tests for horses, dogs and cats. Magnasense receives revenue from the sale of instruments and royalties on the disposable products ie. tests that Salofa sells for the instruments.

When the contract was signed, an order was added to the value of 195,000 Euro (approx. SEK 2 million) for year one.

For additional information, please contact::

Marco Witteveen, CEO, Aegirbio AB

Email: ir@aegirbio.com

About Aegirbio

AegirBio is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, AegirBio was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Aegirbio's website www.aegirbio.com

The company's Certified Adviser is Eminova Fondkomission AB | 08-684 211 00 | info@eminova.se